627 of 1,293 Korean listed borrowers did not earn their 2025 interest bill; the median covered it 1.10 times
Operating income against finance costs for every listed company that reported both. Half the field clears its interest by a tenth. 181 of the 627 were profitable and still fell short. Not advice.
AI-assisted, human-reviewed sourcing. Figures are pulled programmatically from the official sources listed at the end of this article and checked by an editor before publication.
korea interest coverage 2025korea listed companies finance costskospi kosdaq operating income interestkorea corporate debt service 2025dart annual reports
A company that borrows has to earn its interest before it earns anything else. We took every Korean listed company that filed both an operating income figure and a finance cost figure for fiscal 2025 — 1,293 of 2,709 — and divided one by the other.
The median company cleared its interest bill 1.10 times.
Three groups
| Coverage | Companies | Share |
|---|---|---|
| Below 1 times | 627 | 48% |
| 1 to 5 times | 356 | 28% |
| 5 times and above | 310 | 24% |
Nearly half did not cover interest out of operating income. That group is not all loss-makers: 446 of the 627 had an operating loss, and the other 181 were profitable at the operating line and still fell short. For those 181 the shortfall is a financing one rather than a trading one, and no single year says which way it moves next.
Smaller companies carry the weight
| Market value | Companies | Below 1 times | Share |
|---|---|---|---|
| Under 30 billion won | 253 | 190 | 75% |
| 30 to 100 billion | 425 | 219 | 52% |
| 100 to 300 billion | 303 | 122 | 40% |
| 300 billion to 1 trillion | 157 | 50 | 32% |
| 1 to 10 trillion | 108 | 29 | 27% |
| 10 trillion and above | 36 | 7 | 19% |
Three of every four of the smallest borrowers are below 1 times; fewer than one in five of the largest are. The gradient runs the same direction as the net loss rate we counted by the same bands, which is what you would expect when the same companies appear in both counts — this is one list sorted two ways, not two independent findings.
By industry
Among groups with 40 or more companies in the measured set:
| Industry | Companies | Below 1 times | Share |
|---|---|---|---|
| Other machinery and equipment | 99 | 56 | 57% |
| Medicinal substances and pharmaceuticals | 101 | 55 | 54% |
| Wholesale and commission trade | 65 | 35 | 54% |
| Electronic components, computers, communication equipment | 156 | 83 | 53% |
| Medical, precision and optical instruments | 49 | 25 | 51% |
| Publishing | 102 | 48 | 47% |
| Motor vehicles and trailers | 44 | 17 | 39% |
| Food products manufacturing | 44 | 15 | 34% |
| Financial services | 47 | 11 | 23% |
The spread between the top and bottom of this table is 34 percentage points. Pharmaceuticals and precision instruments sit high partly because research spending lands in operating income while the borrowing that funds it lands in finance costs; the ratio reads that as weakness in both halves at once. Financial services sit lowest, and borrowing is their raw material rather than a strain on it.
What this does not measure
More than half the market is absent. 1,358 companies file no finance cost line at all, and we do not read that silence as “no interest” — a company with no borrowings and a company that reports the charge elsewhere look identical here, and we cannot tell them apart from the filing. A further 184 report no operating income figure. Those 1,416 companies are not measured, not zero.
Finance costs as filed can include foreign exchange losses and other charges, so a company near the line may clear it on a narrower definition of interest. Read 1.10 times as the stricter number.
Data & Verification Notes
- Data as of
- Sources
- Financial Supervisory Service (Korea, Open DART) — Annual financial statements (report code 11011), fiscal year 2025: operating income, finance costs
- SeoulMarkets — Korea Valuation Tape, priced 18 November 2026
- Cross-checks
- Companies reporting both operating income and finance costs above zero: 1,293 of 2,709.
- Operating income below finance costs: 627, or 48%. Of those, 446 had an operating loss and 181 were profitable at the operating line and still did not cover interest.
- Coverage ratio, operating income divided by finance costs: below 1 times, 627; 1 to 5 times, 356; 5 times and above, 310. Median 1.10.
- Market value band, companies, below 1 times, share: under 30 billion won, 253, 190, 75%; 30 to 100 billion, 425, 219, 52%; 100 to 300 billion, 303, 122, 40%; 300 billion to 1 trillion, 157, 50, 32%; 1 to 10 trillion, 108, 29, 27%; 10 trillion and above, 36, 7, 19%. These six bands hold 1,282 of the 1,293; 11 have no market value in the data.
- Industry groups with 40 or more companies, share below 1 times: other machinery and equipment 56 of 99, 57%; medicinal substances and pharmaceuticals 55 of 101, 54%; wholesale and commission trade 35 of 65, 54%; electronic components, computers and communication equipment 83 of 156, 53%; medical, precision and optical instruments 25 of 49, 51%; publishing 48 of 102, 47%; motor vehicles and trailers 17 of 44, 39%; food products manufacturing 15 of 44, 34%; financial services 11 of 47, 23%.
- Excluded figures
- 1,416 of 2,709 companies are not measured here: 1,358 report no finance cost figure in the annual filing, 184 report no operating income figure, and one reports finance costs of exactly zero. A missing figure is not a zero and is not counted as full coverage.
- Finance costs as filed. The line can carry foreign exchange losses and other charges alongside interest, so coverage measured this way is the stricter reading.
- One fiscal year. A company below 1 times in 2025 may have been above it in 2024 and may be above it again.
- Market value is one trading day, 18 November 2026, and is used only to sort companies into bands.
- Financial companies borrow as a matter of business. Their 23% share is reported, not interpreted.
- This is a statistic about a list, not about any one company, and not investment advice.
The full dataset behind these figures — every listed company, every row — is available to license. SeoulMarkets data for licence →
Not investment advice. SMarkets publishes data journalism for general information only. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security — any investment you make is at your own risk and responsibility. Figures are derived from official public data sources and may be revised by the issuing agency. Verify independently before acting.
← More Equities